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Objective: Patients with occlusive or aneurysmal vascular disease are repeatedly exposed to intravascular (IV) contrast for
diagnostic or therapeutic purposes. We sought to determine the long-term impact of cumulative iodinated IV contrast
exposure (CIVCE) on renal function; the latter was deﬁned by means of National Kidney Foundation (NKF) criteria.
Methods: We performed a longitudinal study of consecutive patients without renal insufﬁciency at baseline (NFK stage I or
II) who underwent interventions for arterial occlusive or aneurysmal disease.We collected detailed data on any IV iodinated
contrast exposure (including diagnostic or therapeutic angiography, cardiac catheterization, IV pyelography, computed
tomography with IV contrast, computed tomographic angiography); medication exposure throughout the observation
period; comorbidities; and demographics. The primary end pointwas the development of renal failure (RF) (deﬁned asNFK
stage 4 or 5). Analysis was performed with the use of a shared frailty model with clustering at the patient level.
Results: Patients (n[ 1274) had a mean follow-up of 5.8 (range, 2.2-14) years. In the multivariate model with RF as the
dependent variable and after adjusting for the statistically signiﬁcant covariates of baseline renal function (hazard ratio
[HR], 0.95; P < .001), diabetes (HR, 1.8; P[ .007), use of an angiotensin-converting enzyme inhibitor (HR, 0.63; P[
.03), use of antiplatelets (HR, 0.5; P [ .01), cumulative number of open vascular operations performed (HR, 1.2; P [
.001), and congestive heart failure (HR, 3.2; P < .001), CIVCE remained an independent predictor for RF development
(HR, 1.1; P < .001). In the multivariate survival analysis model and after adjusting for the statistically signiﬁcant
covariates of perioperative myocardial infarction (HR, 3.9; P < .001), age at entry in the cohort (HR, 1.05; P [ .035),
total number of open operations (HR, 1.51; P < .001), and serum albumin (HR, 0.47; P < .001), CIVCE was an in-
dependent predictor of death (HR, 1.07; P < .001).
Conclusions: Cumulative IV contrast exposure is an independent predictor of RF and death in patients with occlusive and
aneurysmal vascular disease. (J Vasc Surg 2014;59:1644-50.)Chronic renal dysfunction can lead to progressive
morbidity after advanced endovascular procedures and
has been independently associated with all-cause mortal-
ity.1 Especially after endovascular aortic aneurysm repair,
32-51% of patients will progress to chronic kidney disease
(CKD) at 18 months.2 Several risk factors that lead to
worsening of renal function after endovascular procedures
have been identiﬁed,3-5 with contrast-induced nephropathy
(CIN) being among the most important.
Although CIN has been mostly associated with acute
kidney injury after contrast-enhanced studies through
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4medullary hypoxia,7 there is potential for chronic oxidative
stress from a single or cumulative intravascular contrast expo-
sure (CIVCE) as well as radiation exposure and probably
other unknown factors. This risk is particularly important in
vascular patients with either occlusive or aneurysmal disease
undergoing repeated contrast-enhancedprocedures for diag-
nostic, therapeutic, or surveillance purposes.
In the present study, we hypothesized that CIVCE
adversely affects long-term renal function and survival after
diagnostic or therapeutic procedures are performed in pa-
tients with occlusive or aneurysmal vascular disease.
METHODS
Patient population and data extraction. With the
use of a retrospective cohort design, charts of consecutive
patients who underwent elective operations for atheroscle-
rotic vascular occlusive or aneurysmal disease in a single
institution over a 14-year period (January 1999 to
December 2012) were reviewed. We included patients
who underwent carotid endarterectomy, open or endovas-
cular intervention for aortoiliac occlusive disease, open or
endovascular intervention for infrainguinal occlusive dis-
ease, and aneurysm repair (either open or endovascular).
We excluded patients whom on initial presentation had
CKD stage 4 or 5 as this represented the main outcome of
Table I. Patient characteristics on entry in the study
Variables No. %
Stage I 461 36.2
Stage II 576 45.2
Stage III 227 18.6
HTN 1094 85.9
Hyperlipidemia 969 76.1
CAD 579 45.4
COPD 319 25.0
CHF 137 10.8
Diabetes 472 37.0
Black race 266 20.9
Plavix 185 14.5
ACE inhibitor 682 53.5
Aspirin 889 69.8
b-blockers 738 57.9
Statin 888 69.7
EVAR 356 18
Aortoiliac interventions 353 18
Infrainguinal interventions 989 51
CEA 228 12
Open AAA repair 19 1
Stage Age, mean (range) Baseline eGFR, mean (range)
Stage I 61 (41-86) 108 (90.1-175.3)
Stage II 62 (40-89) 73.8 (60-89.9)
Stage III 65 (48-89) 51.1 (31.3-59.9)
AAA, Abdominal aortic aneurysm; ACE, angiotensin-converting enzyme;
CAD, coronary artery disease; CEA, carotid endarterectomy; CHF,
congestive heart failure; COPD, chronic obstructive pulmonary disease;
eGFR, estimated glomerular ﬁltration rate; EVAR, endovascular aneurysm
repair; HTN, hypertension; Stage, stage of chronic kidney disease at
baseline.
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period less than 2 years because we assumed that this
would be a rather short time frame for the cumulative effect
of contrast administration to become clinically signiﬁcant.
Exposures of interest. The objective of the study was
to assess the association between CIVCE and the develop-
ment of renal failure (RF) deﬁned as CKD stages 4 or 5
according to National Kidney Foundation (NKF) guide-
lines.8 To calculate the CIVCE, we collected data on
every exposure to iodinated contrast media that was pre-
sent in the patient’s chart starting from the year 1999. This
included contrast used for computed tomography, digital
subtraction angiography, cardiac catheterization, and
intravenous pyelography. The CIVCE was calculated as the
running total of individual IV contrast exposures for each
particular patient.
Covariates of interest. Data were collected through
review of charts located in the electronic medical record
system. The Veterans Health Administration (VHA) has
implemented a nationwide electronic medical record sys-
tem that allows instant access to patient information even
if interventions, admissions, or laboratory work are per-
formed in different VHA facilities. Because most of the vet-
erans tend to seek care within the VHA, capturing patient
information in a comprehensive and accurate manner is
feasible. Covariates of interest included demographics,
comorbidities, medications on record at the time of each
hospital admission, operative information, vascular and
open-heart operations, baseline and postoperative labora-
tory values, and death. The cumulative number of open
vascular reconstructions and open cardiac surgeries that
were performed on the patients was also captured and
included in the multiple regression models to adjust for the
impact of surgical stress on the outcomes of interest.
Outcomes. The primary outcome was the develop-
ment of CKD stage 4 or 5 as deﬁned according to NKF
criteria outlined below. The secondary outcome was overall
patient survival.
Renal failure. For the purposes of this study, RF was
deﬁned as the development of CKD either stage 4
(estimated glomerular ﬁltration rate [eGFR] between
15-29 mL$min1 per 1.73 m2) or stage 5
(eGFR <15 mL$min1 per 1.73 m2) any time during
the observation period, even though in some cases this
was not permanent because some patients reversed back
from stage 4 or 5 to stage 3 or 2. eGFR was determined
by use of the Chronic Kidney Disease Epidemiology
Collaboration equation.9 CKD stage 1-5 was classiﬁed on
the basis of the NKF/Kidney Disease Outcome Quality
Initiative criteria.8
We collected data on eGFR at various time points
throughout each individual patient’s follow-up period.
These included baseline values on patient entry and exit
of the cohort; values before a test was performed that
necessitated IV contrast use; values at admission and
discharge for every hospital admission; and values for every
time that the patient’s CKD stage changed. Given the
extent of the follow-up and the multiple time points usedper patient, appropriate computer logic was used to clean
the data from spurious values caused by lab error. Specif-
ically, eGFR values that were indicative of CKD status
change of two stages or more were veriﬁed as being accu-
rate when there was a conﬁrmatory similar value obtained
within 48 hours. Similar veriﬁcation was performed for
eGFR values that were found to deviate more than 2 stan-
dard deviations from the mean eGFR value of the three
previous time periods.
Survival. Survival was captured as freedom from all-
cause inpatient and outpatient deaths.
Statistical analysis. We conducted time-to-event an-
alyses through the use of a parametric regression model
with shared frailty at the patient level. Both outcomes
were modeled by means of the Weibull distribution to
capture the hypothesized effect of contrast on renal
function, which mainly occurs at the time of contrast
administration and subsequently diminishes over time.
The information in the covariates of interest was struc-
tured through the use of a panel data conﬁguration to
allow capturing information for multiple admissions and
contrast exposures for individual patients. Results from
simple and multiple regressions are presented as hazard
ratios (HRs). This is the ratio of the hazard rates that
correspond to the conditions described by two levels of
Fig 1. Kaplan-Meier estimates for freedom from stage 4 or 5 chronic kidney disease (CKD).
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diabetes indicates that diabetic subjects have 20% greater
risk of having the outcome under investigation at any
given point during the study period.10 CIVCE was
analyzed as a continuous variable when computing sim-
ple and multiple regression to identify predictors of RF
and survival and as a categorical variable when calculating
Kaplan-Meier estimates of freedom from RF and survival.
In the latter case, the cutoffs for CIVCE were set at 300
and 650 mL, values that represented the 33rd and 67th
percentiles of CIVCE in our patient population. For
these analyses, the HR expresses the hazard for the
outcome to occur in patients receiving (1) between 300
and 650 mL of contrast and (2) more than 650 mL of
contrast compared with the referent of 300 mL of
contrast or less. All analyses were performed with the use
of Stata version 12.1 (StataCorp, College Station, Tex).
RESULTS
Descriptive statistics. Information was available on
1274 consecutive patients who were followed up for an
average of 5.8 (range, 2.2-14) years and had a median of
three (range, 0-27) interventions involving the use of a me-
dian amount of 460 mL (range, 0-3581 mL) of IV
contrast. The mean age was 62 (range, 40-89) years on en-
try in the study. Details of the patient population on entry
in the study are presented in Table I. The progression to
CKD stage 4 or 5 was permanent in 115 (9%) and transient
in 420 (33%) patients.
Impact of CIVCE on freedom from RF. The
Kaplan-Meier estimates of freedom from RF at 4 years
were 87%, 80%, and 64% for patients who had received
cumulative contrast <300 mL, between 300-650 mL, and
>650 mL, respectively. The estimates for freedom from RFat 8 years were 53%, 46%, and 40% for patients who had
received cumulative contrast <300 mL, between 300-
650 mL, and >650 mL, respectively (P < .001; Fig 1).
Independent predictors for the development of
RF. Univariate analysis showed a statistically signiﬁcant as-
sociation between cumulative contrast administration and
the development of RF (HR, 1.12; P < .001; Table II).
In the multiple regression model, CIVCE remained an
independent predictor for the development of RF (HR,
1.1; P < .001) after adjusting for the statistically signiﬁcant
covariates of baseline renal function (HR, 0.95; P < .001),
diabetes (HR, 1.8; P ¼ .007), congestive heart failure (HR,
3.2; P < .001), use of an angiotensin-converting enzyme
inhibitor (HR, 0.63; P ¼ .036), and use of antiplatelets
(HR, 0.51; P < .01). Patients who underwent carotid
endarterectomy were less likely to progress to CKD stages
4 and 5 in the univariate analysis; however, multiple
regression indicated that there was no association between
the type of vascular operation and renal function deterio-
ration (Table III).
Impact of CIVCE on survival. The Kaplan-Meier
estimates of survival at 4 years were 96%, 91%, and 84% for
patients who had received cumulative contrast <300 mL,
between 300-650 mL, and >650 mL, respectively. The es-
timates of survival at 8 years was 90%, 80%, and 69% for
patients who had received cumulative contrast <300 mL,
between 300-650 mL, and >650 mL, respectively (P <
.001; Fig 2).
Independent predictors of survival. Univariate anal-
ysis showed a statistically signiﬁcant association between
cumulative contrast administration and death (HR, 1.21;
P < .001; Table IV). In the multiple regression model,
CIVCE remained an independent predictor of death (HR,
1.07; P ¼ .003) after adjusting for the statistically
Table III. Multivariate regression model that
summarizes the independent predictors of stages
4 and 5 chronic kidney disease (CKD)
Variables HR (95% CI) P value
CIVCE 1.1 (1.07-1.15) <.001
Baseline eGFR 0.95 (0.94-0.96) <.001
Diabetes mellitus 1.8 (1.16-2.7) .007
Congestive heart failure 3.2 (2.05-5.19) <.001
Use of ACE inhibitors 0.63 (0.45-0.87) .03
Use of antiplatelets 0.51 (0.3-0.85) .01
Total open operations 1.2 (1.07-1.31) .001
AAA, Abdominal aortic aneurysms; ACE, angiotensin-converting enzyme;
CEA, carotid endarterectomy; CI, conﬁdence interval; CIVCE, cumulative
intravenous contrast exposure (in increments of 100 mL); EVAR, endo-
vascular aneurysm repair; eGFR, estimated glomerular ﬁltration rate at entry
in the study cohort;HR, hazard ratio; Open heart, open heart surgery, either
coronary bypass or valve repair; Total open operations, total number of
cardiac and vascular operations that the patients underwent during the
observation time.
Table II. Univariate analysis that outlines predictors
studied for association with development of stages 4 and
5 chronic kidney disease (CKD)
Variables HR (95% CI) P value
CIVCE 1.12 (1.08-1.16) <.001
eGFR 0.95 (0.94-0.96) <.001
Age at entry 1.26 (0.89-1.79) .184
Diabetes mellitus 2.63 (1.74-4.00) <.001
CHF 4.81 (3.02-7.66) <.001
Black 0.60 (0.28-1.28) .187
Aspirin 0.90 (0.60-1.36) .623
Plavix 0.83 (0.53-1.30) .419
EBL 1.02 (1.01-1.03) <.001
Hypertension 1.96 (0.83-4.62) .123
Hyperlipidemia 0.93 (0.55-1.57) .779
No history of smoking 0.72 (0.51-1.03) .074
Drop in Hgb 0.67 (0.60-0.75) <.001
b-blockers 1.13 (0.75-1.72) .560
Statins 1.23 (0.81-1.85) .333
ACE inhibitor 0.93 (0.66-1.32) .688
Total open operations 1.26 (1.15-1.38) <.001
CAD 1.52 (1.00-2.30) .051
COPD 0.87 (0.54-1.41) .572
Open heart 2.23 (0.78-5.4) .311
Cardiac catheterization 1.94 (1.24-4.58) .041
Antiplatelets 0.58 (0.35-0.96) .034
EVAR Reference Reference
Aortoiliac open 1.11 (0.51-2.40) .800
Aortoiliac endovascular 0.38 (0.13-1.07) .067
CEA 0.37 (0.16-0.84) .018
Infrainguinal open 1.59 (0.88-2.88) .127
Infrainguinal endovascular 1.35 (0.77-2.35) .293
Open AAA 5.62 (1.03-30.6) .046
BMI 1.01 (0.97-1.05) .627
ACE, Angiotensin-converting enzyme; BMI, body mass index; CAD, cor-
onary artery disease; CHF, congestive heart failure; CI, conﬁdence interval;
CIVCE, cumulative intravenous contrast exposure (in increments of
100 mL); COPD, chronic obstructive pulmonary disease; EBL, estimated
intraoperative blood loss of open vascular operations; eGFR, estimated
glomerular ﬁltration rate; HR, hazard ratio; Drop in Hgb, difference be-
tween baseline serum hemoglobin and nadir postoperative serum hemo-
globin; Open heart, open heart surgery, either coronary bypass or valve
repair; Total open operations, total number of cardiac and vascular operations
that the patients underwent during the observation time.
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(HR, 3.9; P < .001), age at entry to the cohort (HR, 1.05;
P ¼ .035), total number of open cardiac or vascular op-
erations (HR, 1.51; P < .001), and serum albumin (HR,
0.4; P < .001; Table V).
DISCUSSION
In this retrospective study, we analyzed the long-term
effect of repeated IV contrast exposure on renal function
and survival in patients without advanced renal insufﬁ-
ciency at baseline who underwent interventions for vascular
occlusive and aneurysmal disease. We showed that CIVCE
was an independent predictor for both development of
stage 4 or 5 CKD and increased mortality rates. Our study
is unique in that (1) analyzed a broad patient population
that shares the common feature of need for repeated
contrast exposure, and (2) had a long time horizon toevaluate associations between contrast and the outcome
variables.
The association between amount of contrast used for
endovascular procedures and CIN is well known. Most of
the published data focuses mainly on the development of
acute kidney injury that occurs shortly after the administra-
tion of the contrast load.11,12 However, recent re-
ports2,5,13-17 studying patients after endovascular aortic
aneurysm repair have raised the possibility of a long-term
adverse effect of repeated contrast use on renal function.
Whereas vascular surgeons remain cognizant of issues
related to changes of renal function after endovascular
aortic aneurysm repair because of the need for periodic
use of contrast, our data indicate that the decline in renal
function appears to be a more generalized phenomenon
related to IV contrast use. It is also likely that the effect
of cumulative IV contrast on renal function is not limited
to patients who receive vascular surgery, although this pa-
tient population represents an ideal initial patient cohort to
study this problem because of the need for periodic use of
contrast for diagnostic, therapeutic, or surveillance
purposes.
The mechanism that underlies the harmful effect of
repeated contrast exposure on kidney function is unclear.
First, use of contrast may be a surrogate marker for other
comorbidities that may also lead to deterioration of renal
function. However, our models were adjusted for baseline
renal function as well as the presence of congestive heart
failure, diabetes mellitus, and hypertension. Second, there
may be a direct contrast-related cytotoxic effect.7 Third,
changes in blood viscosity or patient hemodynamics may
alter local renal hemodynamics and may result in regional
hypoxia.7 The latter mechanism is insidious but may be
of particular importance, as evidenced by the fact that the
number of open vascular operations was an independent
predictor for the development of stages 4 and 5 CKD;
dehydration and hemodynamic lability that accompany an
Fig 2. Kaplan-Meier estimates for survival.
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causing progressive and irreversible damage of the renal
parenchyma.
Previous studies reporting ﬁndings on the evolution
of renal function in patients with vascular disease have
studied mixed populations with respect to baseline renal
function or have examined the impact of contrast load
on patients with some degree of renal insufﬁciency
(CKD stage 3 or higher). In our analysis and in addi-
tion to patients with CKD stage 3, we included individ-
uals with CKD stages 1 or 2 (eGFR >60 mL$min1 per
1.73 m2) at baseline. The rationale behind this was
twofold: ﬁrst, to examine the impact of cumulative IV
contrast administration in a patient population that
has traditionally received little attention in randomized
trials of renal protection regimens; and second, to pro-
vide a more homogeneous patient cohort with respect
to baseline risk factors and facilitate risk-adjusted anal-
ysis. Our ﬁndings support the notion that patients
with CKD stages 1 through 3 at baseline are at risk
of development of RF after repeated contrast exposure.
In light of this, future trials should place some emphasis
on assessing the value of renal protection measures in
these patients.
Lack of standardization and various deﬁnitions of renal
dysfunction have compromised the generalizability of ﬁnd-
ings and comparison of outcomes between studies looking
into CIN.13 In our view, any long-term assessment of renal
function should be based on well-validated and widely
accepted criteria. With this rationale, we used the CKD
staging system as described by the NKF/Kidney Disease
Outcomes Quality Initiative, which represents the standard
in evaluation and management of CKD.The ﬁrst main ﬁnding of this study was that CIVCE is
associated with the development of either transient or per-
manent stage 4 or 5 CKD. Admittedly, permanent RF has
attracted most of the attention in the renal nephropathy
literature because it has a direct impact on patient quality
of life and death. Our ﬁndings indicate that the effect of cu-
mulative contrast load on renal function is insidious as 33%
of our cohort had transient development and 9% had per-
manent development of RF. This is a substantial number,
particularly considering that 82% of the patients that we
examined were at CKD stage 1 or 2 at baseline. The phys-
iologic consequences of this phenomenon remain to be
determined.
Our ﬁndings indicate that CIVCE was an indepen-
dent predictor of overall survival. This was after fairly
robust risk adjustment for comorbidities, including the
interval development of RF that is well known to affect
survival. However, caution should be used when inter-
preting this association. The need for higher repeated
contrast exposure may simply indicate a higher baseline
disease burden whose individual components were not
possible to capture in a retrospective analysis. Despite
this obvious limitation, this ﬁnding is intriguing enough
to warrant further investigation in future prospective
studies.
There are multiple limitations in this study that
might result in bias and are inherent to its retrospective
design. The VHA electronic medical record system is
robust. However, it is possible that patients had IV
contrast administered outside of the VHA system, and
this was not documented in the electronic medical re-
cord. As such, it is not possible to fully account for
the exact amount of contrast that any given patient
Table V. Multivariate regression model that summarizes
the independent predictors of mortality
Variables HR (95% CI) P value
Cumulative amount of contrast 1.07 (1.03-1.11) .003
Perioperative MI 3.9 (1.98-7.67) <.001
Albumin 0.47 (0.35-0.62) <.001
Age at entry 1.05 (1.03-1.67) .035
Total open operations 1.51 (1.37-1.67) <.001
CI, Conﬁdence interval; HR, hazard ratio; MI, myocardial infarction; Total
open operations, total number of cardiac and vascular operations that the
patients underwent during the observation time.
Table IV. Univariate analysis that outlines predictors
studied for association with overall patient mortality
Variables HR (95% CI) P value
CIVCE 1.21 (1.13-1.29) <.001
Baseline eGFR 1.00 (0.99-1.01) .922
Age 1.06 (1.04-1.08) <.001
Diabetes mellitus 0.66 (0.44-0.98) .038
CHF 0.88 (0.54-1.45) .619
Black race 0.91 (0.49-1.34) .414
ASA 0.91 (0.63-1.31) .617
Plavix 0.94 (0.61-1.45) .785
EBL 1.02 (1.01-1.03) <.001
Hypertension 0.93 (0.53-1.65) .808
Hyperlipidemia 0.58 (0.40-0.84) .004
Drop in Hgb 0.35 (0.021-1.91) .285
b-blockers 0.67 (0.48-0.93) .016
Statins 0.90 (0.62-1.31) .596
ACE inhibitors 0.78 (0.56-1.07) .127
Total open operations 1.97 (1.67-2.33) <.001
Open heart operations 1.34 (0.61-5.84) .348
Cardiac catheterization 1.73 (0.61-8.32) .286
CAD 1.25 (0.85-1.82) .253
COPD 1.91 (1.38-2.65) <.001
BMI 0.94 (0.90-0.98) .008
Antiplatelets 0.91 (0.89-0.94) .02
EVAR Reference Reference
Aortoiliac open 0.37 (0.14-1.01) .053
Aortoiliac endovascular 0.50 (0.19-1.33) .165
CEA 0.34 (0.12-0.96) .041
Infrainguinal open 0.70 (0.37-1.35) .290
Infrainguinal endovascular 0.72 (0.41-1.28) .267
Open AAA 0.98 (0.95-1.02) .999
AAA, Abdominal aortic aneurysm; ACE, angiotensin-converting
enzyme; BMI, body mass index; CAD, coronary artery disease;
CEA, carotid endarterectomy; CHF, congestive heart failure; CI,
conﬁdence interval; CIVCE, cumulative intravenous contrast exposure
(in increments of 100 mL); COPD, chronic obstructive pulmonary
disease; Drop in Hgb, difference between baseline serum hemoglobin
and nadir postoperative serum hemoglobin; EBL, estimated intra-
operative blood loss of open vascular operations; eGFR, estimated
glomerular ﬁltration rate at entry in the study cohort; EVAR, endo-
vascular aneurysm repair; HR, hazard ratio; Total open operations,
total number of cardiac and vascular operations that the patients
underwent during the observation time.
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exact exposure length for some of the important covari-
ates, particularly medications, was not easy to ascertain.
Again, this is further confounded by the fact that some
patients receive medications not reﬂected in the VHAelectronic medical record. Last, we identiﬁed that open
cardiac and vascular surgical reconstruction was an inde-
pendent predictor of development of stage 4 or 5 CKD.
During the observation time, some of the patients were
likely to have nonvascular open surgical procedures that
were not captured in our dataset. Postoperative compli-
cations linked to these operations might have contrib-
uted to the progression to higher stages of CKD, but
is not captured in our analysis.
CONCLUSIONS
We have shown that in patients without renal insufﬁ-
ciency who undergo interventions for occlusive or aneu-
rysmal vascular disease, the CIVCE is an independent
predictor for the development of transient or permanent
stage 4 or 5 CKD and death. In view of these results, a pro-
spective study to verify these ﬁndings and expand them to
patients without a history of vascular disease appears to be
appropriate.
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